Aprovel (irbesartan) and Co-Aprovel (irbesartan and hydrochlorothiazide)
APROVEL® (irbesartan) is an angiotensin II receptor antagonists (AIIRA) indicated as a first-line treatment for hypertension and renal disease in patients with hypertension and type 2 diabetes mellitus1. It helps to relax blood vessels and permit normalization of arterial blood pressure. In addition to Aprovel, Sanofi markets COAPROVEL®, a fixed-dose combination of irbesartan and hydrochlorothiazide, a thiazide diuretic provide a greater antihypertensive effect by promoting the excretion of salts and water by the kidneys1.
Aprovel and Co-Aprovel are proven in clinical studies that gets over 80% of patients to blood pressure goal and are very well tolerated. Registered and launched in Hong Kong in 1998, Aprovel is also approved in Europe and in the U.S., for the treatment of diabetic nephropathy in hypertensive patients suffering from type 2 diabetes2.
Reference:1. Aprovel and CoAprovel Hong Kong Prescribing Information. | 2. Littlejohn et al. Long-term Safety and Antihypertensive Efficacy of Irbesartan: Pooled Results of Five Open-label Studies. Clin. And Exper. Hypertension, 21(8), 1273-1295 (1999).
CLEXANE® (enoxaparin) is a type of low molecular weight heparin, indicated for treating or significantly reducing the incidence of venous thromboembolism disease in a broad spectrum of patients, as well as in effectively preventing, in conjunction with other treatments, the ischemic complications of unstable angina and non-Q-wave myocardial infarction1.
The most common side effect includes Haemorrhage, haemorrhagic anaemia and thrombocytopenia1.
Clexane was registered in Hong Kong in 1996.
Reference:1. Clexane Hong Kong Prescribing Information.
MULTAQ® (Dronedarone), discovered and developed by Sanofi, is an anti-arrhythmic drug for the treatment of non-permanent AF. Its efficacy and safety was evaluated in five controlled studies involving nearly 7,000 patients including more than 3,200 patients who received Multaq1. FDA has approved Multaq in July 2009, followed by the approval by European Medicines Agency (EMEA) in December 2009. Multaq was registered and marketed in Hong Kong in April 2010 and July 2010 respectively2.
Multaq is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Treatment with Multaq can be initiated in an outpatient setting. Most common adverse reactions are diarrhea, nausea, asthenia (weakness) and cutaneous rash1.
Reference: 1. Multaq Hong Kong Prescribing Information. | 2. Multaq U.S. and EU Prescribing Information
Plavix® (clopidogrel) is an antiplatelet taken once a day that helps keep platelets in the blood from sticking together and forming clots. It is indicated for the long-term prevention of atherothrombotic events in patients with acute coronary syndrome (myocardial infarction and unstable angina), stroke or peripheral arterial disease1.
Plavix is currently indicated for the secondary prevention of atherothrombosis, irrespective of the location of the arteries initially affected (heart, brain or lower limbs), on the basis of the results of the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) study demonstrating the superior efficacy of Plavix versus aspirin with a comparable safety profile2.
Over 100 million patients worldwide have been treated with Plavix. In Hong Kong, Plavix was registered in 1998 and has become available in the market since April, 19993.
Reference: 1. Plavix Hong Kong Prescribing Information. | 2. CAPRIE Steering Committee. Lancet 1996; 348: 1329–39. | 3. Data on file
Praluent® is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor as an adjunct to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C1,2. Praluent is taken by self-injection and comes in pre-filled pens. It is the first PCSK9 inhibitor available in 2 starting doses (75mg and 150mg) in 1ml of solution1,2.
In clinical studies of patients with heart problems due to plaque in the arteries or with HeFH whose bad (LDL) cholesterol was not at goal despite being on the highest tolerated dose of a statin, adding Praluent reduced bad cholesterol an additional 50-61%3-4. The most common adverse reactions are nasopharyngitis, injection site reactions and influenza1-2.
Praluent got U.S Food & Drug Administration (FDA) approval in Jul 2015 and it was approved in the European Union (EU) in Sep 2015. Praluent was approved by the Department of Health of Hong Kong in Oct 2016.
Reference:1. Praluent 75mg Hong Kong Prescribing Information. | 2. Praluent 150mg Hong Kong Prescribing Information. | 3. Cannon CP, Cariou B, Blom D et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36;1186-1194. | 4. Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;3721:1489-1499.